Sign up
Quantellect · Analysts · Analyst Profile
Q Score Rank#111 of 388

Joel Beatty

Baird · Equity Research Analyst
ProvisionalRating since 2022No new ratings since Jun 2025

Analyst rating accuracy & track record

Joel Beatty is an equity research analyst at Baird. Quantellect has scored 23 of their stock calls across 13 companies. Their picks beat their sector 46% of the time over the next 12 months, and their price targets were reached 35% of the time within a year.

Win % vs sector
46%
PT Hit % (12mo)
35%
Avg sector-excess
−0.8%
Scored calls
23
Tickers
13
Tier
Provisional

Track record

Quantellect has scored 23 of Joel Beatty's stock calls across 13 companies, dating back to 2022. Their rated stocks beat their own sector 46% of the time over the next 12 months. On a typical call, a Beatty pick returned −0.8% more than its sector over the following year.

Of the scored calls, 23 were bullish (Buy). Most of their coverage sits in Unknown. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
FURYFury Gold Mines Ltd
BuyJun 2025−12.7%
EDITEditas Medicine Inc
Buy$4.00May 2025+94.2%Hit
DNTHDianthus Therapeutics Inc.
Buy$50.00May 2025+337.7%Hit
DNLIDenali Therapeutics Inc
Buy$29.00May 2025+26.5%Miss
LRMRLarimar Therapeutics Inc
Buy$10.00Mar 2025+105.2%Miss
CTNMContineum Therapeutics, Inc. Class A Common Stock
Buy$16.00Mar 2025+76.7%Hit
CPRXCatalyst Pharmaceuticals Inc
Buy$32.00Mar 2025+0.6%Miss
CPRXCatalyst Pharmaceuticals Inc
Buy$28.00Feb 2025+0.1%Miss
EDITEditas Medicine Inc
Buy$8.00Dec 2024+50.8%Miss
AMLXAmylyx Pharmaceuticals Inc
Buy$11.00Nov 2024+157.3%Hit
IMMPImmutep Ltd ADR
Buy$7.00Nov 2024−14.9%Miss
CTNMContineum Therapeutics, Inc. Class A Common Stock
Buy$32.00Oct 2024−30.9%Miss
LRMRLarimar Therapeutics Inc
Buy$16.00Sep 2024−47.0%Miss
IMMPImmutep Ltd ADR
Buy$6.00Jun 2024−11.9%Miss
CLDICalidi Biotherapeutics Inc.
Buy$2.00May 2024−96.0%Hit
CLDICalidi Biotherapeutics Inc.
Buy$4.50Mar 2024−96.8%Miss
CLDICalidi Biotherapeutics Inc.
Buy$9.00Oct 2023−130.1%Miss
IMMPImmutep Ltd ADR
Buy$7.00Aug 2023+10.6%Miss
IMMPImmutep Ltd ADR
Buy$7.00Aug 2023−21.0%Miss
IMMPImmutep Ltd ADR
Buy$7.00Aug 2023−17.3%Miss
INMBINmune Bio Inc
Buy$16.00Jun 2023+8.2%Miss
BYSIBeyondSpring Inc
Buy$1.25May 2023+123.6%Hit
CRDFCardiff Oncology Inc
Buy$6.00Aug 2022−31.6%Miss
Go to

Joel Beatty: analyst track record FAQ

Is Joel Beatty a good stock analyst?

Yes, by track record. Joel Beatty ranks number 111 of 388 of the analysts Quantellect scores, with a Q Score of 48 out of 100. Past results do not guarantee future ones.

What is Joel Beatty's win rate?

Joel Beatty's win rate is 46%. Across 23 scored calls, their rated stocks beat their sector 46% of the time over the next 12 months. On a typical call they returned −0.8% more than the sector.

What stocks and sectors does Joel Beatty cover?

Joel Beatty covers 13 companies, with the most coverage in Unknown. See the ratings table above for every scored call and its outcome.

Are Joel Beatty's price targets accurate?

Joel Beatty's price targets are reached within 12 months 35% of the time. The base rate across all analysts Quantellect tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Quantellect scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Joel Beatty's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Quantellect score analyst accuracy?

Quantellect scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Joel Beatty rank among Wall Street analysts?

Joel Beatty ranks number 111 of 388 by Q Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Quantellect calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.